Non-Viral iPS Cell Reprogramming Without Chromosome Integration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing induced pluripotent stem cells (iPS cells) rely on viral vectors like retroviruses, which pose safety concerns due to integration into the chromosome and associated risks of tumorigenesis and ethical issues related to embryo destruction.

Innovation Solution

A method using non-viral expression vectors, such as plasmid vectors, to introduce genes encoding reprogramming factors into somatic cells, avoiding integration into the chromosome and thereby reducing safety risks and ethical concerns.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If viral vectors (retrovirus or lentivirus) are used to introduce reprogramming factor genes into somatic cells, then the efficiency of gene delivery and reprogramming is improved, but safety issues arise due to chromosome integration and potential tumorigenesis

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidsafety

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent extracts the harmful integration function from the gene delivery system by using non-viral expression vectors that do not integrate into chromosomes. This separates the useful function (gene delivery) from the harmful function (chromosome integration), thereby maintaining reprogramming efficiency while eliminating safety risks associated with tumorigenesis

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces non-viral expression vectors as an intermediary medium to deliver reprogramming factor genes without the harmful properties of viral vectors. These vectors serve as a safe mediator that achieves gene delivery without chromosome integration, resolving the contradiction between delivery efficiency and safety

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If viral vectors are used for gene delivery, then efficient introduction of reprogramming factor genes is achieved, but ethical issues related to embryo destruction and tumorigenesis risks are introduced

Engineering Contradiction:

Improvegene delivery efficiencyVSAvoidethical issues and safety risks

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent converts the limitation of non-viral vectors (lower delivery efficiency) into a benefit by eliminating all safety and ethical hazards. The non-viral expression vectors, while less efficient than viral vectors, provide a completely safe alternative that avoids tumorigenesis risks and ethical controversies, thereby transforming a technical disadvantage into a safety advantage

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20230282445A1Method of nuclear reprogramming

Publication Date: 2023.09.07 KYOTO UNIV

AI summary

A method of producing an induced pluripotent stem cell, comprising the step of introducing at least one kind of non-viral expression vector incorporating at least one gene that encodes a reprogramming factor into a somatic cell. In some embodiments, the gene that encodes a reprogramming factor is one or more kind of genes selected from the group consisting of an Oct family gene, a Klf family gene, a Sox family gene, a Myc family gene, a Lin family gene, and the Nanog gene.